#Zentiva #Czech Republic #Prague #Urban Wastewater Directive #EU Court Decision

Zentiva Takes a Stand Against EU's Urban Wastewater Directive

Zentiva, a European leader in the generics sector, is actively challenging a decision made by the Court of Justice of the European Union (CJEU) regarding the Urban Wastewater Treatment Directive (UWWTD). This directive has raised significant worries over its implications for the availability and affordability of essential medicines across Europe. On April 27, 2026, Zentiva and other generic pharmaceutical companies initiated an appeal against a previous ruling that deemed their case inadmissible, aiming for a substantive judicial review.

The directive's implementation has ignited concern among 24 of the 27 EU member states, who have expressed doubts about its repercussions. Despite these concerns, the directive is progressing at a national level, potentially threatening millions of patients who rely on accessible medicines. Zentiva is requesting a temporary suspension and reevaluation of the directive, asserting that significant risks are present regarding drug availability and affordability.

While Zentiva supports the goal of reducing micro-pollutants present in urban wastewater, it vehemently opposes the proposed extended producer responsibility (EPR) system. This system would impose undue financial burdens on pharmaceutical and cosmetics manufacturers for contaminants they did not produce, effectively violating the principle that 'the polluter pays'. Such costs could lead to further restrictions on the viability of supplying essential medicines, ultimately affecting patient access. As Steffen Saltofte, CEO of Zentiva and president of Medicines for Europe, emphasizes, excessive costs on essential medications risk rendering them unaffordable for patients.

Currently, generic medicines constitute about 70% of all prescriptions in Europe and are crucial for public health. However, these manufacturers operate under strict price regulations, limiting their capacity to adjust prices in response to increased costs unlike many other sectors. Research indicates that the financial implications of the UWWTD have been grossly underestimated, leading to potential shortages of critical medicines and posing a significant threat to the competitiveness of the entire pharmaceutical sector.

Zentiva is bringing this issue to the forefront, seeking to reverse the CJEU's order of inadmissibility regarding their case to ensure that core legal principles of the EU are upheld while maintaining patient access to affordable medications. The legal challenge specifically targets Articles 9 and 10, along with Annex III of the UWWTD, which link the EPR to funding up to 80% of new wastewater treatment costs involving pharmaceuticals and cosmetics.

Despite the direct and individual impact of the UWWTD on Zentiva and other generic companies, they have been denied a thorough examination of their case by the earlier court ruling. Zentiva stresses that this legal action is fundamental to protect patients' rights to affordable medicines and safeguard public health, showing their commitment to environmental responsibility while ensuring that access to necessary treatments is not compromised.

Zentiva promotes health and well-being, focusing on developing, producing, and distributing high-quality, affordable medicines to millions of people in over 40 countries. With a robust operational framework, including four manufacturing plants and a network of external partners, Zentiva employs over 5,400 professionals, dedicated to supporting those who depend on their products. For further information, visit Zentiva's website or their LinkedIn page.

In conclusion, this appeal is not only about legalities but reflects a broader commitment to balancing environmental sustainability with the pressing needs of public health. As this case unfolds, it occupies a significant place in the intersection of health and environmental policy within the EU.